Research ExplorerPublicationsThe association of the type and number of D'Amico high-risk ...

The association of the type and number of D'Amico high-risk criteria with rates of pathologically non-organ-confined prostate cancer

Standard

The association of the type and number of D'Amico high-risk criteria with rates of pathologically non-organ-confined prostate cancer. / Chierigo, Francesco; Flammia, Rocco Simone; Sorce, Gabriele; Hoeh, Benedikt; Hohenhorst, Lukas; Tian, Zhe; Saad, Fred; Gallucci, Michele; Briganti, Alberto; Montorsi, Francesco; Chun, Felix K H; Graefen, Markus; Shariat, Shahrokh F; Guano, Giovanni; Mantica, Guglielmo; Borghesi, Marco; Suardi, Nazareno; Terrone, Carlo; Karakiewicz, Pierre I.

In: CENT EUR J UROL, Vol. 76, No. 2, 2023, p. 104-108.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Chierigo, F, Flammia, RS, Sorce, G, Hoeh, B, Hohenhorst, L, Tian, Z, Saad, F, Gallucci, M, Briganti, A, Montorsi, F, Chun, FKH, Graefen, M, Shariat, SF, Guano, G, Mantica, G, Borghesi, M, Suardi, N, Terrone, C & Karakiewicz, PI 2023, 'The association of the type and number of D'Amico high-risk criteria with rates of pathologically non-organ-confined prostate cancer', CENT EUR J UROL, vol. 76, no. 2, pp. 104-108. https://doi.org/10.5173/ceju.2023.030

APA

Chierigo, F., Flammia, R. S., Sorce, G., Hoeh, B., Hohenhorst, L., Tian, Z., Saad, F., Gallucci, M., Briganti, A., Montorsi, F., Chun, F. K. H., Graefen, M., Shariat, S. F., Guano, G., Mantica, G., Borghesi, M., Suardi, N., Terrone, C., & Karakiewicz, P. I. (2023). The association of the type and number of D'Amico high-risk criteria with rates of pathologically non-organ-confined prostate cancer. CENT EUR J UROL, 76(2), 104-108. https://doi.org/10.5173/ceju.2023.030

Vancouver

Chierigo F, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Tian Z et al. The association of the type and number of D'Amico high-risk criteria with rates of pathologically non-organ-confined prostate cancer. CENT EUR J UROL. 2023;76(2):104-108. https://doi.org/10.5173/ceju.2023.030

Bibtex

@article{4a84bd29ce0f456498efd630a44d4855,
title = "The association of the type and number of D'Amico high-risk criteria with rates of pathologically non-organ-confined prostate cancer",
abstract = "INTRODUCTION: The aim of this study was to assess the association between the type and number of D'Amico high-risk criteria (DHRCs) with rates of pathologically non-organ-confined (NOC) prostate cancer in patients treated with radical prostatectomy (RP) and pelvic lymphadenectomy (PLND).MATERIAL AND METHODS: In the Surveillance, Epidemiology, and End Results database (2004-2016), we identified 12961 RP and PLDN patients with at least one DHRC. We relied on descriptive statistics and multivariable logistic regression models.RESULTS: Of 12 961 patients, 6135 (47%) exclusively harboured biopsy Gleason score (GS) 8-10, 3526 (27%) had clinical stage ≥T2c, and 1234 (9.5%) had prostate-specific antigen (PSA) >20 ng/mL. Only 1886 (15%) harboured any combination of 2 DHRCs. Finally, all 3 DHRCs were present in 180 (1.4%) patients. NOC rates increased from 32% for clinical T stage ≥T2c to 49% for either GS 8-10 only or PSA >20 ng/mL only and to 66-68% for any combination of 2 DHRCs, and to 84% for respectively all 3 DHRCs, which resulted in a multivariable logistic regression OR of 1.00, 2.01 (95% CI 1.85-2.19; p <0.001), 4.16 (95% CI 3.69-4.68; p <0.001), and 10.83 (95% CI 7.35-16.52; p <0.001), respectively.CONCLUSIONS: Our study indicates a stimulus-response effect according to the type and number of DHRCs. Hence, a formal risk-stratification within high-risk prostate cancer patients should be considered in clinical decision-making.",
author = "Francesco Chierigo and Flammia, {Rocco Simone} and Gabriele Sorce and Benedikt Hoeh and Lukas Hohenhorst and Zhe Tian and Fred Saad and Michele Gallucci and Alberto Briganti and Francesco Montorsi and Chun, {Felix K H} and Markus Graefen and Shariat, {Shahrokh F} and Giovanni Guano and Guglielmo Mantica and Marco Borghesi and Nazareno Suardi and Carlo Terrone and Karakiewicz, {Pierre I}",
note = "Copyright by Polish Urological Association.",
year = "2023",
doi = "10.5173/ceju.2023.030",
language = "English",
volume = "76",
pages = "104--108",
journal = "CENT EUR J UROL",
issn = "2080-4806",
publisher = "Panstwowy Zaklad Wydawnictw Lekarskich",
number = "2",

}

RIS

TY - JOUR

T1 - The association of the type and number of D'Amico high-risk criteria with rates of pathologically non-organ-confined prostate cancer

AU - Chierigo, Francesco

AU - Flammia, Rocco Simone

AU - Sorce, Gabriele

AU - Hoeh, Benedikt

AU - Hohenhorst, Lukas

AU - Tian, Zhe

AU - Saad, Fred

AU - Gallucci, Michele

AU - Briganti, Alberto

AU - Montorsi, Francesco

AU - Chun, Felix K H

AU - Graefen, Markus

AU - Shariat, Shahrokh F

AU - Guano, Giovanni

AU - Mantica, Guglielmo

AU - Borghesi, Marco

AU - Suardi, Nazareno

AU - Terrone, Carlo

AU - Karakiewicz, Pierre I

N1 - Copyright by Polish Urological Association.

PY - 2023

Y1 - 2023

N2 - INTRODUCTION: The aim of this study was to assess the association between the type and number of D'Amico high-risk criteria (DHRCs) with rates of pathologically non-organ-confined (NOC) prostate cancer in patients treated with radical prostatectomy (RP) and pelvic lymphadenectomy (PLND).MATERIAL AND METHODS: In the Surveillance, Epidemiology, and End Results database (2004-2016), we identified 12961 RP and PLDN patients with at least one DHRC. We relied on descriptive statistics and multivariable logistic regression models.RESULTS: Of 12 961 patients, 6135 (47%) exclusively harboured biopsy Gleason score (GS) 8-10, 3526 (27%) had clinical stage ≥T2c, and 1234 (9.5%) had prostate-specific antigen (PSA) >20 ng/mL. Only 1886 (15%) harboured any combination of 2 DHRCs. Finally, all 3 DHRCs were present in 180 (1.4%) patients. NOC rates increased from 32% for clinical T stage ≥T2c to 49% for either GS 8-10 only or PSA >20 ng/mL only and to 66-68% for any combination of 2 DHRCs, and to 84% for respectively all 3 DHRCs, which resulted in a multivariable logistic regression OR of 1.00, 2.01 (95% CI 1.85-2.19; p <0.001), 4.16 (95% CI 3.69-4.68; p <0.001), and 10.83 (95% CI 7.35-16.52; p <0.001), respectively.CONCLUSIONS: Our study indicates a stimulus-response effect according to the type and number of DHRCs. Hence, a formal risk-stratification within high-risk prostate cancer patients should be considered in clinical decision-making.

AB - INTRODUCTION: The aim of this study was to assess the association between the type and number of D'Amico high-risk criteria (DHRCs) with rates of pathologically non-organ-confined (NOC) prostate cancer in patients treated with radical prostatectomy (RP) and pelvic lymphadenectomy (PLND).MATERIAL AND METHODS: In the Surveillance, Epidemiology, and End Results database (2004-2016), we identified 12961 RP and PLDN patients with at least one DHRC. We relied on descriptive statistics and multivariable logistic regression models.RESULTS: Of 12 961 patients, 6135 (47%) exclusively harboured biopsy Gleason score (GS) 8-10, 3526 (27%) had clinical stage ≥T2c, and 1234 (9.5%) had prostate-specific antigen (PSA) >20 ng/mL. Only 1886 (15%) harboured any combination of 2 DHRCs. Finally, all 3 DHRCs were present in 180 (1.4%) patients. NOC rates increased from 32% for clinical T stage ≥T2c to 49% for either GS 8-10 only or PSA >20 ng/mL only and to 66-68% for any combination of 2 DHRCs, and to 84% for respectively all 3 DHRCs, which resulted in a multivariable logistic regression OR of 1.00, 2.01 (95% CI 1.85-2.19; p <0.001), 4.16 (95% CI 3.69-4.68; p <0.001), and 10.83 (95% CI 7.35-16.52; p <0.001), respectively.CONCLUSIONS: Our study indicates a stimulus-response effect according to the type and number of DHRCs. Hence, a formal risk-stratification within high-risk prostate cancer patients should be considered in clinical decision-making.

U2 - 10.5173/ceju.2023.030

DO - 10.5173/ceju.2023.030

M3 - SCORING: Journal article

C2 - 37483849

VL - 76

SP - 104

EP - 108

JO - CENT EUR J UROL

JF - CENT EUR J UROL

SN - 2080-4806

IS - 2

ER -